COMP <GO>
INMB vs LONA // GROSS PROFIT MARGIN
INmune Bio Inc. (NASDAQ) VS. LeonaBio Inc. (NASDAQ) • 15-METRIC TALLY: INMB 1
— LONA 2
■ METRIC PARITY
LAST: $1.60 (+4.58%) • MKT CAP: $44.4M
gross-margins
—
LAST: $4.91 (-1.01%) • MKT CAP: $46.3M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INMB VS. LONA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INMB | LONA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | INMB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.5 | 43.7 | -9.26 | LONA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $44.4M | $46.3M | -$1.9M | LONA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INMB REV | LONA REV | INMB GROSS % | LONA GROSS % | INMB FCF | LONA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $50.0K | $0 | — | — | -$23.6M | -$45.7M |
| FY 2024 | $14.0K | $0 | — | — | -$33.4M | -$97.2M |
| FY 2023 | $155.0K | $0 | — | — | -$12.0M | -$100.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INMB // BETA —
LONA // BETA —